Galectins in cancer: Carcinogenesis, diagnosis and therapy

Annals of Translational Medicine

Volumn 2, Issue 9, 2014, Pages

  Ebrahim, Ali Hasan ^a   Alalawi, Zainab ^b   Mirandola, Leonardo ^c,d   Rakhshanda, Rahman ^c,e   Dahlbeck, Scott ^c,f   Nguyen, Diane ^c,f   Jenkins, Marjorie ^d   Grizzi, Fabio ^g   Cobos, Everardo ^c,f   Figueroa, Jose A ^c,f   Chiriva Internati, Maurizio ^c,d,e,f  

^a TEXAS TECH UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d Center for Women's Health and Gender Based Medicine   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f Kiromic Inc   (United States)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Cancer; Galectins; Lectins; Solid tumors

Indexed keywords

EID: 85015466677     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2014.09.12     Document Type: Article

References (48)

1. Cummings RD, Liu FT. Galectins. In: Varki A, Cummings RD, Esko JD, et al. eds. Essentials of Glycobiology. 2nd edition. NY: Cold Spring Harbor Laboratory Press, 2009: Chapter 33.
2. Barondes SH, Cooper DN, Gitt MA, et al. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994;269:20807-10.
3. Dalotto-Moreno T, Croci DO, Cerliani JP, et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 2013;73:1107-17.
4. Simone G, Malara N, Trunzo V, et al. Galectin-3 coats the membrane of breast cells and makes a signature of tumours. Mol Biosyst 2014;10:258-65.
5. Irie A, Yamauchi A, Kontani K, et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 2005;11:2962-8.
6. Demers M, Rose AA, Grosset AA, et al. Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells. Am J Pathol 2010;176:3023-31.
7. Campion CG, Labrie M, Lavoie G, et al. Expression of galectin-7 is induced in breast cancer cells by mutant p53. PLoS One 2013;8:e72468.
8. Nangia-Makker P, Wang Y, Raz T, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer. Int J Cancer 2010;127:2530-41.
9. Compagno D, Gentilini LD, Jaworski FM, et al. Glycans and galectins in prostate cancer biology, angiogenesis and metastasis. Glycobiology 2014;24:899-906.
10. Wang Y, Nangia-Makker P, Tait L, et al. Regulation of prostate cancer progression by galectin-3. Am J Pathol 2009;174:1515-23.
11. Knapp JS, Lokeshwar SD, Vogel U, et al. Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol 2013;31:351-8.
12. Kim HJ, Do IG, Jeon HK, et al. Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol 2013;44:62-8.
13. Huang EY, Chen YF, Chen YM, et al. A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis 2012;3:e251.
14. Huang EY, Chanchien CC, Lin H, et al. Galectin-1 is an independent prognostic factor for local recurrence and survival after definitive radiation therapy for patients with squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2013;87:975-82.
15. Tsai CJ, Sulman EP, Eifel PJ, et al. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. Gynecol Oncol 2013;131:645-9.
16. Liang M, Ueno M, Oomizu S, et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 2008;134:899-907.
17. Kohrenhagen N, Voelker HU, Kapp M, et al. The expression of galectin-1 in vulvar neoplasia. Anticancer Res 2010;30:1547-52.
18. Kuo PL, Huang MS, Cheng DE, et al. Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem 2012;287:9753-64.
19. Hsu YL, Wu CY, Hung JY, et al. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin α6β4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013;34:1370-81.
20. Chung LY, Tang SJ, Sun GH, et al. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 2012;18:4037-47.
21. Kuo P, Bratman S, Shultz D, et al. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin Cancer Res 2014. [Epub ahead of print].
22. Carlini MJ, Roitman P, Nuñez M, et al. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients. Lung Cancer 2014;84:73-8.
23. Hayashi T, Saito T, Fujimura T, et al. Galectin-4, a novel predictor for lymph node metastasis in lung adenocarcinoma. PLoS One 2013;8:e81883.
24. Zhu X, Ding M, Yu ML, et al. Identification of galectin-7 as a potential biomarker for esophageal squamous cell carcinoma by proteomic analysis. BMC Cancer 2010;10:290.
25. Kim SJ, Hwang JA, Ro JY, et al. Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget 2013;4:1461-71.
26. Kim SJ, Choi IJ, Cheong TC, et al. Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 2010;138:1035-45.e1-2.
27. Wu KL, Huang EY, Jhu EW, et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol 2013;48:350-9.
28. Barrow H, Guo X, Wandall HH, et al. Serum galectin-2,-4, and-8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 2011;17:7035-46.
29. Song S, Ji B, Ramachandran V, et al. Overexpressed galectin-3 in pancreatic cancer induces cell proliferation and invasion by binding Ras and activating Ras signaling. PLoS One 2012;7:e42699.
30. Belo AI, van der Sar AM, Tefsen B, et al. Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells. PLoS One 2013;8:e65957.
31. Verschuere T, Toelen J, Maes W, et al. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer 2014;134:873-84.
32. Le Mercier M, Lefranc F, Mijatovic T, et al. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008;229:172-83.
33. Binh NH, Satoh K, Kobayashi K, et al. Galectin-3 in preneoplastic lesions of glioma. J Neurooncol 2013;111:123-32.
34. Braeuer RR, Zigler M, Kamiya T, et al. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 2012;72:5757-66.
35. Lefranc F, Mathieu V, Kiss R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem 2011;2:193-201.
36. Mathieu V, de Lassalle EM, Toelen J, et al. Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol 2012;132:2245-54.
37. Sakaki M, Fukumori T, Fukawa T, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 2010;57:152-7.
38. Straube T, Elli AF, Greb C, et al. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res 2011;30:89.
39. Xu Y, Gu X, Gong M, et al. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. Cancer Biol Ther 2013;14:897-906.
40. Huang CS, Tang SJ, Chung LY, et al. Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer. J Am Soc Nephrol 2014;25:1486-95.
41. Sakaki M, Oka N, Nakanishi R, et al. Serum level of galectin-3 in human bladder cancer. J Med Invest 2008;55:127-32.
42. Cindolo L, Benvenuto G, Salvatore P, et al. galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas. Int J Cancer 1999;84:39-43.
43. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003;63:2251-5.
44. Chiu CG, Strugnell SS, Griffith OL, et al. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010;176:2067-81.
45. Weber KB, Shroyer KR, Heinz DE, et al. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 2004;122:524-31.
46. Shankar J, Wiseman SM, Meng F, et al. Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. J Pathol 2012;228:56-66.
47. Bergero N, De Pompa R, Sacerdote C, et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005;36:908-14.
48. Saffar H, Sanii S, Heshmat R, et al. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma. Am J Clin Pathol 2011;135:454-60.